Author of

• 11692

  +

  P2.10 - Poster Session 2 - Chemotherapy (ID 207)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11742

    +

    P2.10-050 - Efficacy of Denosumab in patients with metastatic lung cancer with EGFR mutations (ID 3285)

    09:30 - 09:30  |  Author(s): H. Kitamura
    • Abstract

    Background
    Denosumab, a fully human monoclonal antibody to RANKL, is expected to improve overall survival better than zoledronic acid when administered in the treatment of bone metastasis from lung cancer. Although the mechanism of prolongation of survival by denosumab for lung cancer patients is unknown, denosumab may have an additional effect other than bone-protective effects. We examined relevance between efficacy of denosumab and EGFR mutation status which is tend to be causal of multiple bone metastasis.

    Methods
    Patients treated by Denosumab with metastatic lung cancer were eligible for the study. We retrospectively analyzed their histological type, EGFR mutation status, chemotherapy, the change of primary lesion and bone metastasis before and after treatment of denosumab.

    Results
    From July 2012 to June 2013, there were 18 patients matched in the analysis.Patients’ characteristics: median age 68.5 years, male/female 9/9, PS0/1/2/3 2/10/4/2, adenocarcinoma/others 15/3, EGFR mutation status Ex19del./L858R/wt or unknown 9/2/7). Seven patients were treated by gefitinib, and in the three of them, reossifications by computed tomography were observed without ostalgia.In none of 11 patients treated by other anticancer drug or followed-up, reossification was seen. Figure 1Figure 2

    Conclusion
    Patients treated with gefitinib may be beneficial by denosumab treatment. Further investigation exploring synergistic effect of denosumab and gefitinib is warranted.